Farampator
Clinical data | |
---|---|
Other names | CX-691; ORG-24448 |
Legal status | |
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Farampator (developmental code names CX-691, ORG-24448, SCH-900460) is an
Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects such as headache, somnolence and nausea. Subjects reporting side effects had significantly higher plasma levels of farampator than subjects without.[citation needed] Additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.[3]
See also
References
- ^ "Farampator - AdisInsight".
- PMID 22886028.
- PMID 17119538.